Skip to main content
TELA logo

TELA · TELA Bio, Inc. · Webcasts, Transcripts & Audio

Track TELA — free
$0.82 -0.04 (-4.64%) At close · Nov 13 Play latest call Q3 2026 earnings call transcript
Market Cap
$37.06M
Shares
45.19M
Volume · Nov 13 129.18K Avg daily vol (3M) 224.59K

TELA Bio, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for TELA Bio, Inc. (TELA), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Earnings call
FY26 · Q3
2026-11-10
TELA Bio, Inc. (TELA) Q3 2026 Earnings Call Transcript
Confident tone Abdominal wound management Ovatex clinical application Patient recovery outcomes
Revenue
$18.96M
▼ 8.4% YoY
Diluted EPS
$-0.16
Gross margin
64.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q2
2026-08-10
TELA Bio, Inc. (TELA) Q2 2026 Earnings Call
Revenue
$19.29M
▼ 4.5% YoY
Diluted EPS
$-0.20
Gross margin
72.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-12
TELA Bio, Inc. (TELA) Q1 2026 Earnings Call Transcript
Confident tone Ovatex LTR product launch Second half 2026 outlook and guidance skew Board of directors refresh
Revenue
$19.06M
▲ 2.9% YoY
Diluted EPS
$-0.21
Gross margin
65.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-24
TELA Bio, Inc. (TELA) Q4 2025 Earnings Call Transcript
Positive tone Product Portfolio and Innovation Commercial Organization Rebuild Sales Rep Hiring and Productivity
Revenue
$20.87M*
▲ 18.2% YoY
Gross margin
65.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-13
TELA Bio, Inc. (TELA) Q3 2025 Earnings Call Transcript
Positive tone Revenue growth and commercial milestones Sales force build-out and productivity Geographic expansion and market access
Revenue
$20.69M
▲ 9.1% YoY
Diluted EPS
$-0.19
Gross margin
67.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-11
TELA Bio, Inc. (TELA) Q2 2025 Earnings Call Transcript
Confident tone Revenue milestone and growth Portfolio transition from niche to broad hernia provider New leadership and execution
Revenue
$20.20M
▲ 25.5% YoY
Diluted EPS
$-0.22
Gross margin
69.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
TELA Bio, Inc. (TELA) Q1 2025 Earnings Call Transcript
Positive tone Revenue growth and guidance Tariff exposure and gross margin Commercial organization expansion
Revenue
$18.52M
▲ 11.5% YoY
Diluted EPS
$-0.25
Gross margin
67.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-20
TELA Bio, Inc. (TELA) Q4 2024 Earnings Call Transcript
Cautious tone Sales force turnover and realignment Product portfolio and market opportunity (OviTex) Commercial strategy: TM/AS team structure
Revenue
$17.65M*
▲ 3.8% YoY
Gross margin
63.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-07
TELA Bio, Inc. (TELA) Q3 2024 Earnings Call Transcript
Confident tone Quarterly revenue growth and product momentum 2025 outlook and guidance International/European expansion
Revenue
$18.96M
▲ 25.9% YoY
Diluted EPS
$-0.42
Gross margin
67.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-12
TELA Bio, Inc. (TELA) Q2 2024 Earnings Call Transcript
Positive tone Q2 revenue growth and headwinds OviTex and LIQUIFIX product portfolio Path to profitability and OpEx discipline
Revenue
$16.09M
▲ 11% YoY
Diluted EPS
$-0.51
Gross margin
68.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
TELA Bio, Inc. (TELA) Q1 2024 Earnings Call Transcript
Confident tone GPO and IDN Contracts LIQUIFIX Product Suite OviTex PRS / Plastic and Reconstructive Surgery
Revenue
$16.60M
▲ 39.4% YoY
Diluted EPS
$-0.23
Gross margin
68.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-21
TELA Bio, Inc. (TELA) Q4 2023 Earnings Call Transcript
Confident tone Product Portfolio Expansion (LIQUIFIX and OviTex IHR) GPO Contracts and Hospital Adoption Operating Losses and Cash Burn
Revenue
$17.00M*
▲ 46.3% YoY
Gross margin
68.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-09
TELA Bio, Inc. (TELA) Q3 2023 Earnings Call Transcript
Revenue
$15.05M
▲ 34.9% YoY
Diluted EPS
$-0.45
Gross margin
69.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-09
TELA Bio, Inc. (TELA) Q2 2023 Earnings Call Transcript
Revenue
$14.49M
▲ 39.3% YoY
Diluted EPS
$-0.46
Gross margin
70.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-04-18
TELA Bio, Inc. (TELA) Q1 2023 Earnings Call Transcript
Revenue
$11.91M
▲ 44.7% YoY
Diluted EPS
$-0.63
Gross margin
66.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-21
TELA Bio, Inc. (TELA) Q4 2022 Earnings Call Transcript
Revenue
$11.62M*
▲ 38.8% YoY
Gross margin
70.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-09
TELA Bio, Inc. (TELA) Q3 2022 Earnings Call Transcript
Revenue
$11.16M
▲ 45.8% YoY
Diluted EPS
$-0.64
Gross margin
65.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-10
TELA Bio, Inc. (TELA) Q2 2022 Earnings Call Transcript
Revenue
$10.41M
▲ 37.7% YoY
Diluted EPS
$-0.88
Gross margin
62.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-10
TELA Bio, Inc. (TELA) Q1 2022 Earnings Call Transcript
Revenue
$8.23M
▲ 40.1% YoY
Diluted EPS
$-0.75
Gross margin
60.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-21
TELA Bio, Inc. (TELA) Q4 2021 Earnings Call Transcript
Revenue
$8.37M*
▲ 47.8% YoY
Gross margin
67.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-10
TELA Bio, Inc. (TELA) Q3 2021 Earnings Call Transcript
Revenue
$7.65M
▲ 44.1% YoY
Diluted EPS
$-0.57
Gross margin
60.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-11
TELA Bio, Inc. (TELA) Q2 2021 Earnings Call Transcript
Revenue
$7.56M
▲ 115.5% YoY
Diluted EPS
$-0.57
Gross margin
67.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-13
TELA Bio, Inc. (TELA) Q1 2021 Earnings Call Transcript
Revenue
$5.88M
▲ 57.7% YoY
Diluted EPS
$-0.56
Gross margin
59.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-24
TELA Bio, Inc. (TELA) Q4 2020 Earnings Call Transcript
Revenue
$5.67M*
▲ 16.5% YoY
Gross margin
64.6%
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-12
TELA Bio, Inc. (TELA) Q3 2020 Earnings Call Transcript
Revenue
$5.31M
▲ 33.7% YoY
Gross margin
61.9%
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-12
TELA Bio, Inc. (TELA) Q2 2020 Earnings Call Transcript
Revenue
$3.51M
▲ 6.2% YoY
Gross margin
59.5%
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-12
TELA Bio, Inc. (TELA) Q1 2020 Earnings Call Transcript
Revenue
$3.73M
▲ 12.7% YoY
Gross margin
59.0%
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-01-10
TELA Bio, Inc. (TELA) Q4 2019 Earnings Call
Revenue
$4.86M*
Gross margin
60.9%
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–28 of 28 webcasts
Key facts CIK 1561921 CUSIP 872381108 13F (30d) 42 filings 38 filers Visit website Investor relations